.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF05_Atezolizumab.Atezolizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF05_Atezolizumab.Atezolizumab| name: | Atezolizumab |
| ATC code: | L01FF05 | route: | intravenous |
| n-compartments | 2 |
Atezolizumab is a humanized monoclonal antibody of the IgG1 isotype that selectively binds to programmed death-ligand 1 (PD-L1). It is used in cancer immunotherapy for several malignancies including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer, and more. It is FDA- and EMA-approved for several cancer indications and continues to be used in clinical practice.
Population pharmacokinetic analysis in cancer patients (adults) across clinical trials (n > 800), both sexes, mostly with advanced solid tumors (including NSCLC, urothelial carcinoma).
Shemesh, CS, et al., & Girish, S (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for immunotherapy of cancer 7(1) 314–None. DOI:10.1186/s40425-019-0791-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/31753029
Felip, E, et al., & Restuccia, E (2021). Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Clinical pharmacology in drug development 10(10) 1142–1155. DOI:10.1002/cpdd.936 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33788415
Shemesh, CS, et al., & Bruno, R (2020). Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacology research & perspectives 8(6) e00685–None. DOI:10.1002/prp2.685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33241650